GENETIC MARKERS OF MYOCARDIAL FIBROSIS: OPPORTUNITY TO PREDICT ADVERSE OUTCOMES IN AORTIC STENOSIS
https://doi.org/10.15829/1560-4071-2018-2-32-38
Abstract
Aim. To evaluate the influence of genetic markers of inflammation and fibrosis on survival rate of patients with non operated aortic stenosis (AS). The search for novel prognostically adverse factors in calcinated AS patients with none surgical treatment remains actual.
Material and methods. During 2,1±0,11 years, 191 patient has been followed up (28,6% males, 78,0±0,60 y. o.) with a “natural course” of AS (aortic valve area ≤2,0 cm2). All fatal outcomes (FO) were collected. Then the clinical, biochemical and echocardiographic parameters were compared, genotypes frequencies and alleles of mononucleotide polymorphisms (MNP) G(-238)A and G(-308)A gene TNF, С(-592)A gene IL-10, Arg25Pro gene TGFβ1 in groups with FO and with none. Life duration towards FO was evaluated.
Results. Fatal outcomes were registered in 71 (37,2%) of patients. Death causes were: myocardial infarction in 5, stroke in 8, sudden death in 10, chronic heart failure (CHF) in 29, thromboembolism in 5, non-cardiac cause in 14. Independent factors associated with FO were: presence of CHF III-IV FC NYHA, creatinine level, aortic valve area, myocardial mass index of the left ventricle and carriage of allele Pro MNP Arg25Pro gene TGFβ1 (р<0,05). Associations of MNP G(-238)A and G(-308)A gene TNF, as MNP С(-592)A gene IL-10 with FO were not found. Mean life duration before death in Pro MNP Arg25Pro gene TGFβ1 carriers was 468,6±99,62 days versus 617,6±77,19 days in non-carriers (р<0,05).
Conclusion. The carriage of allele Pro MNP Arg25Pro gene TGFβ1 can be regarded as one more predictor of fatal outcome in patients with non-operated AS. It is clear that LV myocardial fibrosis, developing in AS patients, might be a factor significantly influencing prognosis.About the Authors
Т. A. TiptevaRussian Federation
Moscow
О. S. Chumakova
Russian Federation
A. N. Brovkin
Russian Federation
Moscow
A. G. Nikitin
Russian Federation
Moscow
N. Е. Reznichenko
Russian Federation
D. A. Zateyshchikov
Russian Federation
References
1. Boeva OI, Shcheglova EV, Yagoda AV, et al. Impact of genotype on the progression of calcific aortic valve stenosis (prospective study). European Heart Journal 2016; 37 (Abstract Supplement), 557.
2. Jian B, Narula N, Li Q-y, et al. Progression of aortic valve stenosis: TGF-β1 is present in calcified aortic valve cusps and promotes aortic valve interstitial cell calcification via apoptosis. Ann Thorac Surg 2003; 75 (2): 457-65.
3. Beaumont J, López B, Hermida N, et al. MicroRNA-122 down-regulation may play a role in severe myocardial fibrosis in human aortic stenosis through TGF-β1 up-regulation. Clinical science 2014; 126 (7): 497-506.
4. Shavelle DM, Katz R, Takasu J, et al. Soluble intercellular adhesion molecule-1 (sICAM-1) and aortic valve calcification in the multi-ethnic study of atherosclerosis (MESA). J Heart Valve Dis 2008; 17 (4): 388-95.
5. Tipteva TA, Chumakova OS, Baklanova TN, et al. Single nucleotide polymorphism C(-592)A of interleukin-10 gene is associated with aortic stenosis. Kremljovskaya Medicina. Clinichesky Vestnik. 2017; 1: 24-31. (In Russ.) Типтева Т. А., Чумакова О. С., Бакланова Т. Н. и др. Однонуклеотидный полиморфизм С(-592)A гена интерлейкин-10 ассоциирован с аортальным стенозом. Кремлевская медицина Клинический вестник 2017; 1: 24-31.
6. Crawley E, Kay R, Sillibourne J, et al. Polymorphic haplotypes of the interleukin-10 5’ flanking region determine variable interleukin-10 transcription and are associated with particular phenotypes of juvenile rheumatoid arthritis. Arthritis and rheumatism 1999; 42 (6): 1101-8.
7. Lin MT, Storer B, Martin PJ, et al. Relation of an interleukin-10 promoter polymorphism to graft-versus-host disease and survival after hematopoietic-cell transplantation. The New England journal of medicine 2003; 349 (23): 2201-10.
8. Khan R, Sheppard R. Fibrosis in heart disease: understanding the role of transforming growth factor-β1 in cardiomyopathy, valvular disease and arrhythmia. Immunology 2006; 118 (1): 10-24.
9. Attaran S, Sherwood R, Dastidar MG, El-Gamel A. Identification of low circulatory transforming growth factor β-1 in patients with degenerative heart valve disease. Interactive cardiovascular and thoracic surgery 2010; 11 (6): 791-3.
10. Ochsner S, Guo Z, Binswanger U, Knoflach A. Tgf-β1 Gene Expression In Stable Renal Transplant Recipients. American Journal of Transplantation Supplement 2002; 2: 234.
11. Nordstrom P, Glader CA, Dahlen G, et al. Oestrogen receptor alpha gene polymorphism is related to aortic valve sclerosis in postmenopausal women. Journal of internal medicine 2003; 254 (2): 140-6.
12. Gaudreault N, Ducharme V, Lamontagne MG, et al. Replication of genetic association studies in aortic stenosis in adults. Am J Cardiol 2011; 108 (9): 1305-10.
13. Orlowska-Baranowska E, Gora J, Baranowski R, et al. Common genetic polymorphisms and haplotypes of chymase gene affect left ventricular hypertrophy in male patients with symptomatic aortic stenosis. European Heart Journal 2013; 34 (suppl 1): 2604.
14. Villar AV, Cobo M, Llano M, et al. Plasma levels of transforming growth factor-β1 reflect left ventricular remodeling in aortic stenosis. PLoS One 2009; 4 (12): e8476.
15. Attaran S., Sherwood R., Dastidar M. G., El-Gamel A. Identification of low circulatory transforming growth factor beta-1 in patients with degenerative heart valve disease. Interact Cardiovasc Thorac Surg 2010; 11(6): 791-3.
Review
For citations:
Tipteva Т.A., Chumakova О.S., Brovkin A.N., Nikitin A.G., Reznichenko N.Е., Zateyshchikov D.A. GENETIC MARKERS OF MYOCARDIAL FIBROSIS: OPPORTUNITY TO PREDICT ADVERSE OUTCOMES IN AORTIC STENOSIS. Russian Journal of Cardiology. 2018;(2):32-38. (In Russ.) https://doi.org/10.15829/1560-4071-2018-2-32-38